

Financial news for CRL dated on 2020-06-03: Stocks That Hit 52-Week Highs On Wednesday

Financial news for CRL dated on 2020-06-02: Stocks That Hit 52-Week Highs On Tuesday

Financial news for CRL dated on 2020-05-13: Benzinga's Top Upgrades, Downgrades For May 13, 2020

Financial news for CRL dated on 2020-05-13: UBS Upgrades Charles River to Buy, Raises Price Target of \$200

Financial news for CRL dated on 2020-05-12: Deutsche Bank Maintains Buy on Charles River, Lowers Price Target to \$174

Financial news for CRL dated on 2020-05-08: JP Morgan Maintains Overweight on Charles River, Raises Price Target to \$180

Financial news for CRL dated on 2020-05-08: SunTrust Robinson Humphrey Maintains Buy on Charles River, Raises Price Target to \$194

Financial news for CRL dated on 2020-05-08: Credit Suisse Maintains Neutral on Charles River, Lowers Price Target to \$159

Financial news for CRL dated on 2020-05-08: Morgan Stanley Maintains Overweight on Charles River, Raises Price Target to \$175

Financial news for CRL dated on 2020-05-08: Citigroup Maintains Buy on Charles River, Raises Price Target to \$190

Financial news for CRL dated on 2020-05-07: Charles River Laboratories Sees FY20 Adj. EPS \$6.75-\$7.10 vs \$6.44

Financial news for CRL dated on 2020-05-07: Charles River Q1 Adj. EPS \$1.840 Beats \$1.470 Estimate, Sales \$707.100M Beat \$691.090M Estimate

Financial news for CRL dated on 2020-05-07: Earnings Scheduled For May 7, 2020

Financial news for CRL dated on 2020-04-21: Benzinga's Top Upgrades, Downgrades For April 21, 2020

Financial news for CRL dated on 2020-04-21: Jefferies Downgrades Charles River to Hold

Financial news for CRL dated on 2020-04-09: Citigroup Maintains Buy on Charles River, Lowers Price Target to \$165

Financial news for CRL dated on 2020-04-06: SunTrust Robinson Humphrey Maintains Buy on Charles River, Raises Price Target to \$130

Financial news for CRL dated on 2020-03-30: Wells Fargo Maintains Overweight on Charles River, Lowers Price Target to \$145

Financial news for CRL dated on 2020-03-30: Charles River Laboratories And Deciphex Form Partnership To 'Enhance Drug Discovery & Development With Digital Pathology'

Financial news for CRL dated on 2020-03-27: Morgan Stanley Upgrades Charles River to Overweight

Financial news for CRL dated on 2020-03-26: Barclays Maintains Equal-Weight on Charles River, Lowers Price Target to \$154

Financial news for CRL dated on 2020-03-23: Shares of several healthcare companies are trading lower amid market volatility. Sunday's fiscal stimulus bill failed a procedural senate vote while the Fed Monday morning announced further stimulus measures to support liquidity.

Financial news for CRL dated on 2020-03-23: CORRECTION: Jefferies Maintains Buy On Charles River Labs, Lowers Target To \$139; Initial Headline Had Incorrect Ticker

Financial news for CRL dated on 2020-03-23: Jefferies Maintains Buy on Charles River Labs, Lowers Price Target to \$139

Financial news for CRL dated on 2020-03-19: Stocks That Hit 52-Week Lows On Thursday

Financial news for CRL dated on 2020-03-17: SunTrust Robinson Humphrey Maintains Buy on Charles River, Lowers Price Target to \$124

Financial news for CRL dated on 2020-03-12: Stocks That Hit 52-Week Lows On Thursday

Financial news for CRL dated on 2020-03-02: Benzinga's Top Upgrades, Downgrades For March 2, 2020

Financial news for CRL dated on 2020-03-02: Deutsche Bank Initiates Coverage On Charles River with Buy Rating, Announces \$190 Price Target

Financial news for CRL dated on 2020-02-19: Stocks That Hit 52-Week Highs On Wednesday

Financial news for CRL dated on 2020-02-18: Wolfe Research Upgrades Charles River to Outperform, Raises Price Target to \$203

Financial news for CRL dated on 2020-02-12: Baird Maintains Outperform on Charles River, Raises Price Target to \$185

Financial news for CRL dated on 2020-02-12: Morgan Stanley Maintains Equal-Weight on Charles River, Raises Price Target to \$176

Financial news for CRL dated on 2020-02-12: 94 Biggest Movers From Yesterday

Financial news for CRL dated on 2020-02-11: CFRA Maintains Strong Buy on Charles River, Raises Price Target to \$180

Financial news for CRL dated on 2020-02-11: 71 Stocks Moving In Tuesday's Mid-Day Session

Financial news for CRL dated on 2020-02-11: Stocks That Hit 52-Week Highs On Tuesday

Financial news for CRL dated on 2020-02-11: Charles River Laboratories Sees FY20 Adj. EPS \$7.45-\$7.60 vs \$7.41 Est.

Financial news for CRL dated on 2020-02-11: Charles River Q4 EPS \$2.01 Beats \$1.83 Estimate, Sales \$691.1M Beat \$685.31M Estimate

Financial news for CRL dated on 2020-02-11: Earnings Scheduled For February 11, 2020

Financial news for CRL dated on 2020-01-16: Charles River Labs Reports Formation Of Strategic Alliance With Fios Genomics

Financial news for CRL dated on 2020-01-10: Kerrisdale Capital To Present Long Thesis On Charles River Laboratories At 4:00 p.m. ET ([Link](#))

Financial news for CRL dated on 2020-01-10: Stocks That Hit 52-Week Highs On Friday

Financial news for CRL dated on 2020-01-10: Benzinga's Top Upgrades, Downgrades For January 10, 2020

Financial news for CRL dated on 2020-01-10: Goldman Sachs Upgrades Charles River to Buy, Raises Price Target to \$170

Financial news for CRL dated on 2020-01-09: Stocks That Hit 52-Week Highs On Thursday

Financial news for CRL dated on 2020-01-08: Benzinga's Top Upgrades, Downgrades For January 8, 2020

Financial news for CRL dated on 2020-01-08: Wells Fargo Initiates Coverage On Charles River with Overweight Rating, Announces \$180 Price Target

Financial news for CRL dated on 2020-01-07: Citigroup Initiates Coverage On Charles River with Buy Rating, Announces \$185 Price Target

Financial news for CRL dated on 2019-12-27: Stocks That Hit 52-Week Highs On Friday

Financial news for CRL dated on 2019-12-20: Stocks That Hit 52-Week Highs On Friday

Financial news for CRL dated on 2019-12-17: Baird Maintains Outperform on Charles River, Raises Price Target to \$165

Financial news for CRL dated on 2019-12-16: Stocks That Hit 52-Week Highs On Monday

Financial news for CRL dated on 2019-12-16: Charles River Labs to Acquire HemaCare for \$380M Cash

Financial news for CRL dated on 2019-12-09: KeyBanc Maintains Overweight on Charles River, Raises Price Target to \$162

Financial news for CRL dated on 2019-11-07: UBS Maintains Neutral on Charles River, Lowers Price Target to \$145

Financial news for CRL dated on 2019-11-06: Charles River Narrows FY19 EPS Guidance From \$6.45-\$6.60 To \$6.50-\$6.60 Vs. \$6.52 Est.

Financial news for CRL dated on 2019-11-06: Charles River Q3 EPS \$1.69 Beats \$1.63 Estimate, Sales \$667.951M Miss \$672.74M Estimate

Financial news for CRL dated on 2019-10-18: Benzinga's Top Upgrades, Downgrades For October 18, 2019

Financial news for CRL dated on 2019-10-18: Bank of America Downgrades Charles River to Neutral

Financial news for CRL dated on 2019-09-16: SunTrust Robinson Humphrey Maintains Buy on Charles River, Raises Price Target to \$162

Financial news for CRL dated on 2019-08-06: Shares of diagnostics and research companies are trading higher in sympathy with Syneos Health, which reported strong Q2 results and raised FY19 guidance.

Financial news for CRL dated on 2019-07-31: Charles River Laboratories Raises FY19 Adj. EPS Guidance From \$6.40-\$6.55 To \$6.45-\$6.60 vs \$6.47 Est.

Financial news for CRL dated on 2019-07-31: Charles River Q2 Ad. EPS \$1.63 Beats \$1.55 Estimate, Sales \$657.6M Miss \$662.51M Estimate

Financial news for CRL dated on 2019-07-31: Earnings Scheduled For July 31, 2019

Financial news for CRL dated on 2019-06-07: Many US-traded stocks are trading higher as recent economic signals have raised the potential for a Federal Reserve rate cut.

Financial news for CRL dated on 2019-05-07: Many stocks are trading lower amid continued uncertainty about the future of trade between the US and China, and concerns on U.S. sanctions on Iran and Venezuela.

Financial news for CRL dated on 2019-05-07: Charles River Q1 EPS \$1.4 Beats \$1.38 Estimate, Sales \$604.569M Beat \$595.66M Estimate

Financial news for CRL dated on 2019-05-07: Earnings Scheduled For May 7, 2019

Financial news for CRL dated on 2019-03-11: KeyBanc Maintains Overweight on Charles River, Raises Price Target to \$151

Financial news for CRL dated on 2019-02-14: 58 Biggest Movers From Yesterday

Financial news for CRL dated on 2019-02-13: 42 Stocks Moving In Wednesday's Mid-Day Session

Financial news for CRL dated on 2019-02-13: Charles River Laboratories shares are trading higher after the company reported Q4 EPS of \$1.49, beating the \$1.40 estimate and Q4 sales of \$601.5 million, beating the \$590.75 million estimate; the company reported it sees FY19 sales growth of 10%-15%.

Financial news for CRL dated on 2019-02-13: Charles River Laboratories Signs Binding Offer To Acquire Citoxlab For ~\$510M In Cash

Financial news for CRL dated on 2019-02-13: Charles River Sees FY19 Adj. EPS \$6.25-\$6.40 vs \$6.35 Est., Sees Sales Growth 10%-15%

Financial news for CRL dated on 2019-02-13: Charles River Q4 Adj. EPS \$1.49 Beats \$1.40 Estimate, Sales \$601.5M Beat \$590.75M Estimate

Financial news for CRL dated on 2019-02-13: Earnings Scheduled For February 13, 2019

Financial news for CRL dated on 2019-01-30: Charles River Labs Reports Deal With Toxys For ToxTracker In North America

Financial news for CRL dated on 2018-12-07: Jim Cramer Shares His Thoughts On JPMorgan, PRA Health Sciences And Funko

Financial news for CRL dated on 2018-12-04: Stocks Which Set New 52-Week High Yesterday, Mon., Dec. 3, 2018

Financial news for CRL dated on 2018-12-04: The Daily Biotech Pulse: ASH Presentations Take The Spotlight, Eiger Gets A New CFO

Financial news for CRL dated on 2018-12-03: Morgan Stanley Maintains Equal-Weight on Charles River, Raises Price Target to \$136

Financial news for CRL dated on 2018-11-08: Raymond James Maintains Outperform on

Charles River, Raises Price Target to \$150

Financial news for CRL dated on 2018-11-08: Baird Maintains Outperform on Charles River, Raises Price Target to \$148

Financial news for CRL dated on 2018-11-08: Stocks Which Set New 52-Week High Yesterday, Wed., Nov. 7, 2018

Financial news for CRL dated on 2018-11-08: RBC Capital Maintains Outperform on Charles River, Raises Price Target to \$147

Financial news for CRL dated on 2018-11-07: The Daily Biotech Pulse: FDA Nod For Bristol-Myers Squibb, Momenta Strikes Patent License Deal With AbbVie

Financial news for CRL dated on 2018-11-07: Charles River Cuts FY18 Adj. EPS Guidance From \$5.85-\$6 To \$5.87-\$5.97 vs \$5.92 Estimate

Financial news for CRL dated on 2018-11-07: Charles River Q3 EPS \$1.53 Beats \$1.38 Estimate, Sales \$585.3M Beat \$567.79M Estimate

Financial news for CRL dated on 2018-11-07: Earnings Scheduled For November 7, 2018

Financial news for CRL dated on 2018-11-04: The Week Ahead In Biotech: Earnings, Conferences, PDUFA Dates, Clinical Trial Results And IPOs

Financial news for CRL dated on 2018-10-16: Charles River Laboratories Wins Five-Year, \$95.7M Contract From National Institute Of Allergy And Infectious Diseases; Co. Will Manage And Provide Staffing For NIAID's Division Of Intramural Research Animal Care Program

Financial news for CRL dated on 2018-09-17: Stocks Which Set New 52-Week High Friday, September 14th

Financial news for CRL dated on 2018-09-17: Baird Maintains Outperform on Charles River, Raises Price Target to \$141

Financial news for CRL dated on 2018-09-14: Stocks Which Set New 52-Week High Yesterday, September 13th

Financial news for CRL dated on 2018-09-11: Morgan Stanley Maintains Equal-Weight on Charles River, Raises Price Target to \$112

Financial news for CRL dated on 2018-09-06: Baird Healthcare Conference Concludes Today, Presenters Include: Charles River, Community Health, Cerus, GTx

Financial news for CRL dated on 2018-08-27: Argus Maintains Buy on Charles River, Raises Price Target to \$140

Financial news for CRL dated on 2018-08-23: Pharma Supplier Charles River Laboratories Has Leading Competitive Position, Raymond James Says In Upgrade

Financial news for CRL dated on 2018-08-23: Benzinga's Top Upgrades, Downgrades For August 23, 2018

Financial news for CRL dated on 2018-08-23: Raymond James Upgrades Charles River to Outperform

Financial news for CRL dated on 2018-08-21: 10 Biggest Price Target Changes For Tuesday

Financial news for CRL dated on 2018-08-21: Credit Suisse Maintains Neutral on Charles River, Lowers Price Target to \$121

Financial news for CRL dated on 2018-08-14: Analyst/Investor Meetings Today For Equifax and Charles River Labs, Respectively

Financial news for CRL dated on 2018-08-13: The Week Ahead: Nvidia, Retailer Earnings In Focus

Financial news for CRL dated on 2018-08-09: Stocks Which Set New 52-Week High Yesterday, August 8th

Financial news for CRL dated on 2018-08-09: Jefferies Maintains Buy on Charles River, Raises Price Target to \$145

Financial news for CRL dated on 2018-08-08: Charles Rivers Raises FY18 Sales Guidance From 18-20% To 19-21%, EPS \$5.77-\$5.92 To \$5.85-\$6.00

Financial news for CRL dated on 2018-08-08: Charles River Q2 EPS \$1.62 Beats \$1.46

Estimate, Sales \$585.3M Beat \$571.33M Estimate

Financial news for CRL dated on 2018-08-08: Earnings Scheduled For August 8, 2018

Financial news for CRL dated on 2018-08-07: Stocks Which Set New 52-Week High Yesterday, August 6th

Financial news for CRL dated on 2018-08-06: Stocks Which Set New 52-Week Highs Friday, August 3rd

Financial news for CRL dated on 2018-07-25: Stocks Which Set New 52-Week High Yesterday, July 24th:

Financial news for CRL dated on 2018-07-23: Stocks Which Set New 52-Week Highs Friday

Financial news for CRL dated on 2018-07-20: Stocks Which Set New 52-Week High Yesterday

Financial news for CRL dated on 2018-07-17: Benzinga's Top Upgrades, Downgrades For July 17, 2018

Financial news for CRL dated on 2018-07-17: RBC Capital Upgrades Charles River to Outperform

Financial news for CRL dated on 2018-06-15: Charles River Laboratories Is A Leader In Biopharma Outsourcing, KeyBanc Says In Upgrade

Financial news for CRL dated on 2018-06-15: Benzinga's Top Upgrades, Downgrades For June 15, 2018

Financial news for CRL dated on 2018-06-15: The Market In 5 Minutes: Tariffs, NXPI, Powell And More

Financial news for CRL dated on 2018-06-15: KeyBanc Upgrades Charles River to Overweight

Financial news for CRL dated on 2018-06-06: Jefferies 2018 Global Healthcare Conference Continues Today, Presenters Include: TherapeuticsMD, Charles River, OSI Systems, Odonate Therapeutics, Syros, Alnylam, Gilead, and Celgene

Financial news for CRL dated on 2018-05-10: Charles River Raises FY18 Adj. EPS Outlook From \$5.67-\$5.82 to \$5.77-\$5.92 vs \$5.76 Est., Sales Growth Outlook From 16-18% to 18-20%

Financial news for CRL dated on 2018-05-10: Charles River Q1 Adj. EPS \$1.38 Beats \$1.26 Estimate, Sales \$493.97M Beat \$480.56M Estimate

Financial news for CRL dated on 2018-05-10: Earnings Scheduled For May 10, 2018

Financial news for CRL dated on 2018-04-20: Benzinga's Top Upgrades, Downgrades For April 20, 2018

Financial news for CRL dated on 2018-04-20: Mitsubishi UFJ Initiates Coverage On Charles River with Neutral Rating, Announces \$115.00 Price Target

Financial news for CRL dated on 2018-03-14: Morgan Stanley Maintains Equal-Weight on Charles River, Raises Price Target to \$102.00

Financial news for CRL dated on 2018-02-14: 5 Biggest Price Target Changes For Wednesday

Financial news for CRL dated on 2018-02-14: Benzinga's Top Upgrades, Downgrades For February 14, 2018

Financial news for CRL dated on 2018-02-14: JP Morgan Maintains Overweight on Charles River, Raises price target to \$120.00

Financial news for CRL dated on 2018-02-14: SunTrust Robinson Humphrey Upgrades Charles River to Buy

Financial news for CRL dated on 2018-02-13: Charles River Labs Acquires MPI Research for \$800M Cash

Financial news for CRL dated on 2018-02-13: UPDATE: Charles River Laboratories Sees FY18 Guidance Including MPI Of \$5.67-\$5.82 vs \$5.58 Est.

Financial news for CRL dated on 2018-02-13: Charles River Laboratories Sees FY18 Adj. EPS \$5.42-\$5.57 vs \$5.58 Est.

Financial news for CRL dated on 2018-02-13: Charles River Laboratories Reports Q4 Adj. EPS \$1.40 vs \$1.25 Est., Sales \$478.5M vs \$474.5M Est.

Financial news for CRL dated on 2018-02-13: Charles River Laboratories Names Dr. Davide Molho President, COO

Financial news for CRL dated on 2018-02-13: Earnings Scheduled For February 13, 2018

Financial news for CRL dated on 2018-02-01: Charles River Labs Reports Investment In High-Throughput Screening Infrastructure, No Terms Disclosed

Financial news for CRL dated on 2018-01-22: Charles River Shares Down 2% Mon. Following SunTrust Downgrade From Buy To Hold

Financial news for CRL dated on 2018-01-19: Evercore ISI Group Initiates Coverage On Charles River with In-Line Rating, Announces \$117.00 Price Target

Financial news for CRL dated on 2018-01-11: Charles River Laboratories Acquires KWS BioTest For ~\$20M

Financial news for CRL dated on 2017-12-13: Benzinga's Top Upgrades, Downgrades For December 13, 2017

Financial news for CRL dated on 2017-12-13: Argus Initiates Coverage On Charles River with Buy Rating, Announces \$120.00 Price Target

Financial news for CRL dated on 2017-11-28: Charles River Labs Reports Success Of Integrated Discovery Project With ENYO Pharma

Financial news for CRL dated on 2017-11-16: Lightning Round: Jim Cramer Advises His Viewers On Mallinckrodt, GoPro And More

Financial news for CRL dated on 2017-11-13: Jefferies Maintains Buy on Charles River, Lowers Price Target to \$124.00

Financial news for CRL dated on 2017-11-10: Bank of America Maintains Buy on Charles River, Lowers Price Target to \$115.00

Financial news for CRL dated on 2017-11-09: Charles River Laboratories Increases FY17 Sales Growth From 8.5-10% to 9.75-10.5%, EPS \$5.00-\$5.15 To \$5.08-\$5.18

Financial news for CRL dated on 2017-11-09: Charles River Laboratories Reports Q3 Adj. EPS \$1.30 vs \$1.22 Est., Sales \$464.2M vs \$458.7M Est.

Financial news for CRL dated on 2017-11-09: Earnings Scheduled For November 9, 2017

Financial news for CRL dated on 2017-10-26: Charles River Labs Reports Partnership With InSphero For In Vitro Drug Discovery, Development

Financial news for CRL dated on 2017-09-19: RBC Capital Initiates Coverage On Charles River with Sector Perform Rating, Announces \$110.00 Price Target

Financial news for CRL dated on 2017-08-09: Charles River Labs Reaffirms FY 2017 Adj. EPS Guidance, Raises Sales Guidance

Financial news for CRL dated on 2017-08-09: Charles River labs Q2 Adj. EPS \$1.29 vs \$1.22 Est., Sales \$469.1M vs \$458.0M Est.

Financial news for CRL dated on 2017-08-09: Earnings Scheduled For August 9, 2017

Financial news for CRL dated on 2017-08-07: Charles River Labs Acquires Brain On-Line for EUR 18M

Financial news for CRL dated on 2017-06-29: Jefferies Highlights A Pair Trade In Pharma: Buy ICON, Hold Tight On INC Research

Financial news for CRL dated on 2017-05-05: 4 Medical Stocks That Could Be Big Winners Next Week

Financial news for CRL dated on 2017-04-07: Charles River Labs Drops to Low of \$86.44 on Volume

Financial news for CRL dated on 2017-04-05: Nimbus Therapeutics, Charles River Labs Report Strategic Partnership to Advance New Therapeutic Programs

Financial news for CRL dated on 2017-02-14: A Peek Into The Markets: U.S. Stock Futures Edge Lower Ahead Of Yellen Speech

Financial news for CRL dated on 2017-02-14: Charles River Labs Sees FY 2017 EPS \$5.00

to \$5.10 vs \$5.05 Est

Financial news for CRL dated on 2017-02-14: Charles River Labs Q4 EPS \$1.21 vs \$1.11 Est, Revenue \$466.8M vs \$441.6M Est

Financial news for CRL dated on 2017-02-14: Earnings Scheduled For February 14, 2017

Financial news for CRL dated on 2017-01-04: Benzinga's Top Upgrades, Downgrades For January 4, 2017

Financial news for CRL dated on 2017-01-04: Evercore ISI Group Upgrades Charles River to Buy

Financial news for CRL dated on 2016-12-16: Goldman Sachs Upgrades Charles River to Neutral

Financial news for CRL dated on 2016-11-30: Benzinga's Top Upgrades

Financial news for CRL dated on 2016-11-30: Barclays Upgrades Charles River to Equal-Weight

Financial news for CRL dated on 2016-11-02: Charles River Labs Narrows FY16 Adj. EPS Outlook from \$4.40-\$4.50 to \$4.44-\$4.49 vs \$4.46 Est.

Financial news for CRL dated on 2016-11-02: Charles River Labs Reports Q3 Adj. EPS \$1.18 vs \$1.13 Est., Sales \$425.7M vs \$434.4M Est.

Financial news for CRL dated on 2016-09-28: Charles River Labs Reports Purchase of Agilux Labs for \$64M in Cash

Financial news for CRL dated on 2016-09-06: UBS Downgrades Charles River to Sell

Financial news for CRL dated on 2016-08-08: Charles River Laboratories Partners with Milner Therapeutics Institute and Consortium

Financial news for CRL dated on 2016-08-03: Charles River Laboratories Raises Fy16 EPS From \$4.32-\$4.45 To \$4.40-\$4.50

Financial news for CRL dated on 2016-08-03: Charles River Laboratories Reports Q2 EPS \$1.20 vs. Est. \$1.10, Rev. \$434.1M vs. Est. \$425M

Financial news for CRL dated on 2016-06-27: Charles River Laboratories announced that it has acquired Blue Stream Laboratories, no terms

Financial news for CRL dated on 2016-06-21: Positives In Charles River Labs 'Largely Reflected In Industry-High Valuation'

Financial news for CRL dated on 2016-06-21: Credit Suisse Initiates Coverage on Charles River at Neutral, Announces \$84.00 PT

Financial news for CRL dated on 2016-05-04: Charles River Laboratories Reports Q1 EPS \$0.98 vs. Est. \$0.90, Rev. \$354.9M vs. Est. \$354.9M

Financial news for CRL dated on 2016-04-26: Gabelli & Co Initiates Coverage on Charles River at Buy

Financial news for CRL dated on 2016-04-13: Charles River Labs Announces \$10M Investment in BioMotiv, Strategic Partnership

Financial news for CRL dated on 2016-02-10: Mid-Morning Market Update: Markets Open Higher; Time Warner Posts Mixed Q4 Results

Financial news for CRL dated on 2016-02-10: Charles Rivers Labs Sees FY16 Sales Growth 20%-23.5%

Financial news for CRL dated on 2016-02-10: Charles Rivers Labs Sees FY16 Adj. EPS \$4.07-\$4.17 vs \$4.16 Est.

Financial news for CRL dated on 2016-02-10: Charles River Labs Reports Q4 GAAP EPS \$0.69, Adj. EPS \$1 vs \$0.94 Est., Sales \$353.9M vs \$349M Est.

Financial news for CRL dated on 2016-02-10: Earnings Scheduled For February 10, 2016

Financial news for CRL dated on 2016-01-07: Wells Fargo Earlier Downgraded Charles River to Outperform

Financial news for CRL dated on 2016-01-07: Charles River Announces Acquisition of WIL Research for \$585M

Financial news for CRL dated on 2015-11-18: Charles River Labs Announces Purchase on Oncotest GmbH for ~\$36M

Financial news for CRL dated on 2015-11-04: Charles River Labs Reports Q3 Adj. EPS \$1.03 vs \$0.94 Est., Sales \$349.5M vs \$340M Est.

Financial news for CRL dated on 2015-10-12: Benzinga's Top Upgrades

Financial news for CRL dated on 2015-10-12: Wells Fargo Upgrades Charles River to Market Perform

Financial news for CRL dated on 2015-08-14: Credit Suisse Assumes Charles River at Neutral, Announces \$84.00 PT

Financial news for CRL dated on 2015-07-30: Charles River Labs Reports Q2 Adj EPS \$0.96 Vs Est \$0.97, Sales \$339.6M Vs Est \$339.59M; Raises FY 2015 EPS To \$3.60-\$3.70 vs Est \$3.64

Financial news for CRL dated on 2015-07-30: Charles River Laboratories, AstraZeneca Renew Strategic Partnership Agreement

Financial news for CRL dated on 2015-07-10: Benzinga's Top Downgrades

Financial news for CRL dated on 2015-07-10: Bank of America Upgrades Charles River to Buy

Financial news for CRL dated on 2015-07-10: Barclays Cuts Charles River Labs, Sees Lack Of Demand Proof Over Long-Term

Financial news for CRL dated on 2015-07-10: Morgan Stanley Maintains Equal-weight on Charles River, Raises PT to \$68.00

Financial news for CRL dated on 2015-07-10: Barclays Downgrades Charles River to Underweight, Maintains \$60.00 PT

Financial news for CRL dated on 2015-07-09: US Stock Futures Jump Ahead Of Jobless Claims Data

Financial news for CRL dated on 2015-07-09: Charles River Laboratories to Acquire Celsis International Ltd.

Financial news for CRL dated on 2015-05-27: Jefferies Boosts Targets Across Pharmaceutical Service Stocks

Financial news for CRL dated on 2015-05-06: Charles River Labs Offers Slideshow Presentation Ahead of Deutsche Bank Conference: Expecting Q2 Adj. EPS to be Similar or Slightly Below \$0.97

Financial news for CRL dated on 2015-05-04: Benzinga's Top Upgrades

Financial news for CRL dated on 2015-05-04: Edward Jones Upgrades Charles River to Buy

Financial news for CRL dated on 2015-04-29: Charles River Labs Reports Q1 Adj. EPS \$0.79 vs \$0.82 Est., Sales \$320.4M vs \$324M Est.; Expecting FY15 Sales Growth 6.5-8%

Financial news for CRL dated on 2015-04-29: Charles River Labs Int'l Reports Q1 Adj EPS \$0.79 Vs Est \$0.82, Revs \$320.4M Vs Est \$323.97M

Financial news for CRL dated on 2015-04-27: Jefferies Previews Booming Biotech Earnings

Financial news for CRL dated on 2015-04-07: Wells Fargo Downgrades Charles River to Underperform

Financial news for CRL dated on 2015-03-26: SunTrust Robinson Humphrey Downgrades Charles River to Neutral, Raises PT to \$88.00

Financial news for CRL dated on 2015-02-24: Charles Rivers Announces CFO Thomas Ackerman Retirement, David Smith Will Takeover CFO role

Financial news for CRL dated on 2015-02-10: Charles Rivers Labs Reports Q4 Adj. EPS \$0.81 vs \$0.71 Est., Sales \$329.5M; Sees FY Adj. EPS \$3.55-\$3.65

Financial news for CRL dated on 2015-02-10: Earnings Scheduled For February 10, 2015

Financial news for CRL dated on 2015-01-23: William Blair Upgrades Charles River to Outperform



Financial news for CRL dated on 2014-12-17: ICON Is Now A Strong Buy: Should It Be In Your Portfolio?

Financial news for CRL dated on 2014-11-04: Credit Suisse Maintains Neutral on Charles River Laboratories International, Inc., Raises PT to \$67.00

Financial news for CRL dated on 2014-11-04: Top 4 NYSE Stocks In The Medical Laboratories & Research Industry With The Highest ROE

Financial news for CRL dated on 2014-10-30: Jefferies Maintains Buy on Charles River Laboratories International, Inc., Raises PT to \$75.00

Financial news for CRL dated on 2014-10-29: Charles River Laboratories International, Inc. Reports Q3 EPS of \$0.86 vs \$0.80 Est; Revenue of \$327.60M vs \$327.09M Est

Financial news for CRL dated on 2014-10-15: SunTrust Robinson Humphrey Upgrades Charles River Laboratories International, Inc. to Buy, Raises PT to \$70.00

Financial news for CRL dated on 2014-08-12: Charles Rivers Holding Investor Meeting: Expecting Q3 Sales Growth in Low-Double Digits Range, Adj. EPS Similar YoY

Financial news for CRL dated on 2014-08-06: Charles River Laboratories International, Inc. Raises FY2014 EPS Guidance from \$3.15-3.25 to \$3.25-3.35 vs \$3.21 Est

Financial news for CRL dated on 2014-08-06: Charles River Laboratories International, Inc. Reports Q2 EPS of \$0.97 vs \$0.82 Est

Financial news for CRL dated on 2014-06-24: SunTrust Robinson Humphrey Initiates Coverage on Charles River Laboratories International, Inc. at Neutral, Announces \$55.00 PT

Financial news for CRL dated on 2014-05-20: UPDATE: Morgan Stanley Reiterates On Charles River Laboratories Following CEO Conference Call

Financial news for CRL dated on 2014-05-01: From Charles River Earnings Conf. Call: Expecting Q2 Adj. EPS Similar to Q1 Level, Expecting Qtr. Stronger Demand, Bookings

Financial news for CRL dated on 2014-04-30: Charles River Laboratories International, Inc. Raises FY2014 EPS Guidance from \$3.00-3.10 to \$3.15-3.25 vs \$3.15 Est, Sees Sales Growth in 9-11% Range, vs Prior Guidance of 3-5% Growth

Financial news for CRL dated on 2014-04-30: Charles River Laboratories International, Inc. Reports Q1 EPS of \$0.82 vs \$0.74 Est; Revenue of \$299.40M vs \$302.08M Est

Financial news for CRL dated on 2014-04-01: , Galapagos Complete Sale of BioFocus and Argenta Service Division Operations to Charles River Laboratories

Financial news for CRL dated on 2014-03-19: KeyBanc Initiates Coverage on Charles River Laboratories International, Inc. at Hold

Financial news for CRL dated on 2014-03-18: Charles River Laboratories CEO Foster: 'Moving Earlier in the Drug Development Process is Going to be Very Important to Us'

Financial news for CRL dated on 2014-03-18: Charles River Laboratories CEO Foster: 'We've Become Critical to the Drug Development Process'

Financial news for CRL dated on 2014-03-18: Charles River Laboratories CEO Foster: 'We've Seen Our Clients Outsource a Lot More Work; They're Focused on Reducing Costs and What Makes Sense for Them'

Financial news for CRL dated on 2014-03-18: Jim Cramer Interviews CEO James C. Foster of Charles River Laboratories on Mad Money

Financial news for CRL dated on 2014-02-26: 10 Healthcare Stocks With Strong Growth For 2014: Investment Idea Of The Day

Financial news for CRL dated on 2014-02-18: Citigroup Initiates Coverage on Charles River Laboratories International, Inc. at Neutral, Announces \$64.00 PT

Financial news for CRL dated on 2014-02-12: Morgan Stanley Feels Confidence in Charles River Laboratories Following Solid 4Q13 EPS Report

Financial news for CRL dated on 2014-02-11: Charles River Laboratories International, Inc. Sees FY2014 EPS \$3.00-3.10 vs \$3.10 Est

Financial news for CRL dated on 2014-02-11: Charles River Laboratories International, Inc. Reports Q4 EPS of \$0.73 vs \$0.68 Est; Revenue of \$289.20M vs \$289.56M Est

Financial news for CRL dated on 2014-02-11: Earnings Scheduled For February 11, 2014

Financial news for CRL dated on 2013-12-12: Bank of America Maintains Neutral on Charles River Laboratories International, Inc., Raises PO to \$55.00

Financial news for CRL dated on 2013-12-11: Raymond James Upgrades Charles River Laboratories International, Inc. to Market Perform

Financial news for CRL dated on 2013-12-03: Charles River Labs Adds \$150M in Shares to Buyback Plan

Financial news for CRL dated on 2013-11-20: Deutsche Bank Initiates Coverage on Charles River Laboratories International, Inc. at Hold, Announces \$55.00 PT

Financial news for CRL dated on 2013-10-29: Charles River Laboratories International, Inc. Reports Q3 EPS of \$0.64 vs \$0.70 Est; Revenue of \$292.10M vs \$290.28M Est

Financial news for CRL dated on 2013-10-02: UPDATE: Cantor Fitzgerald Initiates Coverage on Charles River Laboratories on Good Market Position

Financial news for CRL dated on 2013-10-01: Cantor Fitzgerald Initiates Coverage on Charles River Laboratories International, Inc. at Buy, Announces \$52.00 PT

Financial news for CRL dated on 2013-09-24: Credit Suisse Initiates Coverage on Charles River Laboratories International, Inc. at Neutral, Announces \$50.00 PT

Financial news for CRL dated on 2013-09-17: UBS Initiates Coverage on Charles River Laboratories International, Inc. at Neutral, Announces \$49.00 PT

Financial news for CRL dated on 2013-07-31: Charles River Labs Adds \$100M to Buyback Plan

Financial news for CRL dated on 2013-07-31: Charles River Laboratories International, Inc. Reports Q2 EPS of \$0.73 vs \$0.71 Est; Revenue of \$292.90M vs \$294.19M Est

Financial news for CRL dated on 2013-06-18: UPDATE: Goldman Sachs Downgrades Charles River Laboratories on RMS Guidance Risk

Financial news for CRL dated on 2013-06-18: Goldman Sachs Downgrades Charles River Laboratories International, Inc. to Sell, Lowers PT to \$38.00

Financial news for CRL dated on 2013-06-12: UPDATE: Sterne Agee Resumes Charles River Laboratories at Buy on Multiple Positive Factors

Financial news for CRL dated on 2013-06-11: Sterne Agee Initiates Coverage on Charles River Laboratories International, Inc. at Buy, Announces \$56.00 PT

Financial news for CRL dated on 2013-05-31: Raymond James Downgrades Charles River Laboratories International, Inc. to Underperform

Financial news for CRL dated on 2013-05-14: Charles River Labs Spikes Higher

Financial news for CRL dated on 2013-05-01: Charles River Laboratories International, Inc. Reports Q1 EPS of \$0.69 vs \$0.71 Est; Revenue of \$291.20M vs \$294.54M Est

Financial news for CRL dated on 2013-05-01: Earnings Scheduled For May 1, 2013

Financial news for CRL dated on 2013-04-03: Citigroup Downgrades Charles River Laboratories International, Inc. to Sell, Lowers PT to \$37.00

Financial news for CRL dated on 2013-03-27: Wells Fargo Downgrades Charles River Laboratories International, Inc. to Market Perform

Financial news for CRL dated on 2013-03-18: Benzinga's Top Initiations

Financial news for CRL dated on 2013-03-18: UPDATE: Bank of America Initiates Charles River Laboratories at Neutral on Valuation

Financial news for CRL dated on 2013-03-18: Bank of America Initiates Coverage on Charles River Laboratories International, Inc. at Neutral, Announces \$48.00 PO

Financial news for CRL dated on 2013-02-20: UPDATE: ISI Group Reiterates Neutral Rating, Raises PT on Charles River Laboratories on In-Line 4Q12

Financial news for CRL dated on 2013-02-20: ISI Group Maintains Neutral on Charles River Laboratories International, Inc., Raises PT to \$43.00

Financial news for CRL dated on 2013-02-19: UPDATE: Jefferies Upgraded Charles River Laboratories to Buy on Tailwinds

Financial news for CRL dated on 2013-02-19: Jefferies Upgrades Charles River Laboratories International, Inc. to Buy, Raises PT to \$50.00

Financial news for CRL dated on 2013-02-13: Charles River Laboratories International, Inc. Reports Q4 EPS of \$0.64 vs \$0.60 Est; Revenue of \$280.10M vs \$280.81M Est

Financial news for CRL dated on 2013-02-13: Earnings Scheduled For February 13, 2013

Financial news for CRL dated on 2013-01-14: UPDATE: Sterne Agee Reiterates Buy Rating, Raises PT on Charles River Laboratories

Financial news for CRL dated on 2013-01-14: Sterne Agee Maintains Buy on Charles River Laboratories International, Inc., Raises PT to \$51.00

Financial news for CRL dated on 2013-01-09: CRL CEO Foster: 'Large Drug Companies are Using Small Biotech Companies as their Discovery Engines'

Financial news for CRL dated on 2013-01-09: CRL CEO Foster: 'As Drugs Roll Off Patent, More Companies will Begin to Use Our Services'

Financial news for CRL dated on 2013-01-09: CRL CEO Foster: 'There are Conversations with Several Large Drug Companies'

Financial news for CRL dated on 2013-01-09: Jim Cramer Interviews CEO James C. Foster of Charles River Laboratories on Mad Money

Financial news for CRL dated on 2013-01-08: Charles Rivers Labs Reaffirms 2013 Outlook: EPS \$2.80-2.90

Financial news for CRL dated on 2013-01-07: Charles River Labs Closes Purchase of Majority Ownership of Vital River

Financial news for CRL dated on 2012-12-13: UPDATE: JP Morgan Upgrades Charles River Laboratories to Overweight on Risk/Reward

Financial news for CRL dated on 2012-12-13: Benzinga's Top Upgrades

Financial news for CRL dated on 2012-12-13: JP Morgan Upgrades Charles River Laboratories International, Inc. to Overweight, Raises PT to \$42.00

Financial news for CRL dated on 2012-12-12: Mid-Afternoon Market Update: Bernanke Press Conference Leads to Drop in the Markets

Financial news for CRL dated on 2012-12-12: Mid-Day Market Update: Fed to Continue Stimulus, Markets Rise

Financial news for CRL dated on 2012-12-12: UPDATE: ISI Group Cuts PT to \$39 on Charles River Laboratories Following Negative Guidance

Financial news for CRL dated on 2012-12-12: UPDATE: Charles River Sees FY13 EPS Growing at Higher Rate Than Sales, Sees Cash Flow \$165-175M

Financial news for CRL dated on 2012-12-12: Charles Rivers Reaffirms FY12 Outlook; Sees FY13 EPS \$2.80-2.90 vs \$3.02, Sees Sales Growth 2.5-4.5%

Financial news for CRL dated on 2012-12-07: Top 4 NYSE Stocks In The Biotechnology Industry With The Highest ROA

Financial news for CRL dated on 2012-10-31: UPDATE: Jefferies & Company Reiterates Hold Rating, Raises PT on Charles River Laboratories

Financial news for CRL dated on 2012-10-31: Jefferies & Company Maintains Charles River Laboratories International at Hold, Raises PT from \$35 to \$44

Financial news for CRL dated on 2012-10-30: Charles River Labs Narrows FY EPS Guidance from \$2.63-2.73 to \$2.68-2.73 vs \$2.73 Est

Financial news for CRL dated on 2012-10-30: Charles River Laboratories International Reports Q3 EPS \$0.65 vs \$0.62 Est; Revenues \$278.7M vs \$278.86M Est

Financial news for CRL dated on 2012-10-24: Top 4 NYSE Stocks In The Biotechnology Industry With The Highest Revenue Estimates

Financial news for CRL dated on 2012-10-17: Charles River Laboratories Enters Strategic Partnership with AstraZeneca

Financial news for CRL dated on 2012-09-06: Charles River Opens New Biomedical Diagnostic Facility

Financial news for CRL dated on 2012-08-29: Charles River Acquires Accugenix

Financial news for CRL dated on 2012-08-13: Charles River CEO Foster 'Increasingly, Lab Animal Models will Provide Better Translatable Info to Drug Industry'

Financial news for CRL dated on 2012-08-13: Charles River CEO Foster 'Our Goal is to Get Large Drug Companies to Outsource their Clinical Work to Us'

Financial news for CRL dated on 2012-08-13: Charles River CEO Foster 'We Help Companies with Elimination Process to Decide which Drugs to Keep'

Financial news for CRL dated on 2012-08-13: Jim Cramer Interviews CEO James C. Foster of Charles River Laboratories on Mad Money

Financial news for CRL dated on 2012-08-13: PREVIEW: Jim Cramer to Interview CEO's of Regeneron, Charles River on Mad Money

Financial news for CRL dated on 2012-08-07: Charles River Laboratories Guides FY \$2.63-2.73, Had Seen \$2.60-2.70 vs \$2.69 Est

Financial news for CRL dated on 2012-08-07: Charles River Laboratories International Reports Q2 EPS \$0.75 vs \$0.66 Est; Revenues \$284.7M vs \$286.16M Est

Financial news for CRL dated on 2012-07-31: Charles River Labs Files Mixed Securities Shelf

Financial news for CRL dated on 2012-07-10: UPDATE: ISI Group Initiates Charles River Labs With Underweight, \$34 PT Demand, Preclinical Headwinds

Financial news for CRL dated on 2012-07-10: ISI Group Initiates Coverage on Charles River Laboratories International at Underweight, Announces PT of \$34

Financial news for CRL dated on 2012-05-02: Charles River Laboratories International Reports Q1 EPS \$0.7 vs \$0.65 Est; Revenues \$286M vs \$286.58M Est

Financial news for CRL dated on 2012-04-02: UPDATE: Sterne Agee Raises PT to \$45 on Charles River Laboratories

Financial news for CRL dated on 2012-04-02: Sterne Agee Maintains Charles River Laboratories International at Buy, Raises PT from \$43 to \$45

Financial news for CRL dated on 2012-03-28: UPDATE: Piper Jaffray Downgrades Arena Pharmaceuticals to Neutral

Financial news for CRL dated on 2012-03-27: JP Morgan on MAP Pharmaceuticals Delayed Approval of Levadex

Financial news for CRL dated on 2012-02-13: Charles River Laboratories Guides FY 2012 EPS \$2.60-2.70 vs \$2.64 Est

Financial news for CRL dated on 2012-02-13: Charles River Laboratories International Reports Q4 EPS \$0.69 vs \$0.56 Est; Revenues \$291.00M vs \$282.74M Est

Financial news for CRL dated on 2012-02-13: US Stock Futures Signal Higher Start On Wall Street

Financial news for CRL dated on 2012-02-13: Stocks To Watch For February 13

Financial news for CRL dated on 2012-02-13: Earnings Scheduled For February 13

Financial news for CRL dated on 2012-01-30: Holder & Obama's Propaganda is "Belied by a Troublesome Little Thing Called Facts"

Financial news for CRL dated on 2012-01-10: Benzinga's M&A Chatter for Tuesday January 10, 2012

Financial news for CRL dated on 2012-01-04: JP Morgan Reiterates BioMimetic Therapeutics Neutral

Financial news for CRL dated on 2011-12-15: UPDATE: Citigroup Maintains Neutral, Lowers PT to \$31 on Charles River Laboratories

Financial news for CRL dated on 2011-12-15: Citigroup Lowers PT on Charles River Laboratories to \$31

Financial news for CRL dated on 2011-12-14: UPDATE: Deutsche Bank Lowers PT on Charles River Laboratories to \$28

Financial news for CRL dated on 2011-12-14: Deutsche Bank Maintains Hold After

## Charles River Releases 2012 Guidance

Financial news for CRL dated on 2011-12-14: Charles River Sees 2012 Non-GAAP EPS of \$2.60-2.70 vs 2.67 Est

Financial news for CRL dated on 2011-12-12: Notable Call Options Activity in Charles River Laboratories

Financial news for CRL dated on 2011-12-05: Sterne Agee Maintains Buy, PT of \$43 on Charles River Laboratories

Financial news for CRL dated on 2011-11-28: UPDATE: Piper Jaffray Upgrades Arena Pharma to Overweight and Raises PT to \$3

Financial news for CRL dated on 2011-11-15: UPDATE: Credit Suisse Lowering Price Target on Alimera Sciences

Financial news for CRL dated on 2011-11-14: Sterne Agee Initiates Charles River Laboratories Coverage: Buy, \$43 PT

Financial news for CRL dated on 2011-11-11: pSivida Reports Receipt by Alimera Sciences of Complete Response Letter from FDA for ILUVIEN(r) for DME

Financial news for CRL dated on 2011-11-01: Charles River Laboratories Sees 2011 EPS \$2.40-\$2.45 vs \$2.45 Est (Saw \$2.38-\$2.48)

Financial news for CRL dated on 2011-11-01: Charles River Labs Reports Q3 EPS \$0.57 vs \$0.58 Est; Sales \$277.6M vs \$280.45M Est

Financial news for CRL dated on 2011-09-29: Scientific Consortium Awarded Knockout Mouse Project Grant from the National Institutes of Health

Financial news for CRL dated on 2011-09-28: McNicoll Lewis Vlak Raises PT on Transcept Pharmaceuticals to \$8

Financial news for CRL dated on 2011-08-24: Jefferies Has Hold On Charles River Laboratories

Financial news for CRL dated on 2011-08-23: Charles River Announces New Business Alignment; Doesn't Expect Segment Reporting Change

Financial news for CRL dated on 2011-08-09: UPDATE: Jefferies Lowers PT on Charles River Laboratories to \$33

Financial news for CRL dated on 2011-08-09: Jefferies Lowers PT On Charles River Laboratories To \$33

Financial news for CRL dated on 2011-08-02: Charles River Reports Q2 Cont Ops EPS \$0.66 vs \$0.60 Est; Revenues \$288.3M vs \$287.90M Est

Financial news for CRL dated on 2011-07-20: Jefferies Reports FDA Votes Against BMJ Dapagliflozin Approval

Financial news for CRL dated on 2011-07-19: Who Wants to Buy Some Drugs?

Financial news for CRL dated on 2011-05-05: Jefferies Raises PT On Charles River Laboratories To \$44

Financial news for CRL dated on 2011-05-04: J.P. Morgan Reports "Generally Soft" 1Q Results For Charles River Laboratories

Financial news for CRL dated on 2011-05-04: Goldman Sachs Reports Charles River Laboratories EPS Higher Than Expected (CRL)

Financial news for CRL dated on 2011-05-04: JP Morgan Raises PT On Charles River Laboratories To \$38

Financial news for CRL dated on 2011-05-03: Charles River Labs Reports EPS of \$0.61 vs. \$0.55 Estimate; Revenues \$285.8M vs. \$279.17M Estimate

Financial news for CRL dated on 2011-03-03: Charles River to Supply Pfizer's Genetically Modified Research Models

Financial news for CRL dated on 2011-02-24: Charles River Implements \$150M Accelerated Stock Repurchase Program

Financial news for CRL dated on 2011-02-17: Deutsche Bank Reiterates Hold On XenoPort (XNPT)

Financial news for CRL dated on 2011-02-10: Wells Fargo Raises CRL Valuation Range To \$44-\$45 from \$42-\$43

Financial news for CRL dated on 2011-02-10: Jefferies Lowers PT Of Charles River Laboratories To \$35 (CRL)

Financial news for CRL dated on 2011-02-10: Jefferies Raises PT On Charles River Laboratories To \$40

Financial news for CRL dated on 2011-02-09: CRL Revenue Exceeds Jefferies Estimate By \$3.6M

Financial news for CRL dated on 2011-02-09: Goldman Sachs Remains Neutral On Charles River Laboratories (CRL)

Financial news for CRL dated on 2011-02-02: Setback for Orexigen - Analyst Blog

Financial news for CRL dated on 2011-02-02: Setback for Orexigen - Analyst Blog

Financial news for CRL dated on 2011-01-31: Earnings Preview: Alkermes - Analyst Blog

Financial news for CRL dated on 2011-01-31: Earnings Preview: Alkermes - Analyst Blog

Financial news for CRL dated on 2011-01-27: Cost Control Helps Amylin Cut Loss - Analyst Blog

Financial news for CRL dated on 2011-01-27: Cost Control Helps Amylin Cut Loss - Analyst Blog

Financial news for CRL dated on 2011-01-25: Boost for VRX-GSK Epilepsy Drug - Analyst Blog

Financial news for CRL dated on 2011-01-25: Boost for VRX-GSK Epilepsy Drug - Analyst Blog

Financial news for CRL dated on 2011-01-25: Jefferies Pharmaceuticals Update (CRL, PPDI, WX)

Financial news for CRL dated on 2011-01-24: Charles River Laboratories Adds Two New Board Members

Financial news for CRL dated on 2011-01-24: AstraZeneca Responds to FDA Letter - Analyst Blog

Financial news for CRL dated on 2011-01-24: AstraZeneca Responds to FDA Letter - Analyst Blog

Financial news for CRL dated on 2011-01-20: PPDI Guides Above Expectations - Analyst Blog

Financial news for CRL dated on 2011-01-20: MannKind in Jeopardy - Analyst Blog

Financial news for CRL dated on 2011-01-20: PPDI Guides Above Expectations - Analyst Blog

Financial news for CRL dated on 2011-01-20: MannKind in Jeopardy - Analyst Blog

Financial news for CRL dated on 2011-01-14: Good News for Cumberland Pharma - Analyst Blog

Financial news for CRL dated on 2011-01-14: Good News for Cumberland Pharma - Analyst Blog

Financial news for CRL dated on 2011-01-10: Endo Pharma Receives CRL - Analyst Blog

Financial news for CRL dated on 2011-01-10: Endo Pharma Receives CRL - Analyst Blog

Financial news for CRL dated on 2011-01-10: Oppenheimer Maintains ENDP Rating, Estimates And PT

Financial news for CRL dated on 2011-01-07: Valeant's 2011 Outlook Impresses - Analyst Blog

Financial news for CRL dated on 2011-01-07: Valeant's 2011 Outlook Impresses - Analyst Blog

Financial news for CRL dated on 2011-01-04: Recall of Liver Drug by CPIX - Analyst Blog

Financial news for CRL dated on 2011-01-04: Recall of Liver Drug by CPIX - Analyst Blog

Financial news for CRL dated on 2010-12-29: Theravance Evenly Poised - Analyst Blog

Financial news for CRL dated on 2010-12-29: Theravance Evenly Poised - Analyst Blog

Financial news for CRL dated on 2010-12-29: Cephalon Drops Jet Lag Indication - Analyst Blog

Financial news for CRL dated on 2010-12-29: Verdict on MNKD's Afrezza Deferred - Analyst Blog

Financial news for CRL dated on 2010-12-29: Cephalon Drops Jet Lag Indication - Analyst Blog

Financial news for CRL dated on 2010-12-29: Verdict on MNKD's Afrezza Deferred - Analyst Blog

Financial news for CRL dated on 2010-12-28: CRL for Alimera's Eye drug - Analyst Blog

Financial news for CRL dated on 2010-12-28: CRL for Alimera's Eye drug - Analyst Blog

Financial news for CRL dated on 2010-12-28: Alimera Sciences: Iluvien Approval Delayed By FDA

Financial news for CRL dated on 2010-12-27: FDA Rejection Sends pSivida Shares Down 20.1% (PSDV)

Financial news for CRL dated on 2010-12-27: Afternoon Market Update

Financial news for CRL dated on 2010-12-27: Setback for Cumberland Pharma - Analyst Blog

Financial news for CRL dated on 2010-12-27: Vivus Seeks EU Nod for Qnexa - Analyst Blog

Financial news for CRL dated on 2010-12-27: Setback for Cumberland Pharma - Analyst Blog

Financial news for CRL dated on 2010-12-27: Vivus Seeks EU Nod for Qnexa - Analyst Blog

Financial news for CRL dated on 2010-12-27: Benzinga's Top Pre-Market NASDAQ Losers (PSDV, TSLA, MGIC, NFLX)

Financial news for CRL dated on 2010-12-27: A Peek Into The Market Before The Trading Starts

Financial news for CRL dated on 2010-12-27: Oppenheimer Has Outperform Rating On Alimera Sciences (ALIM)

Financial news for CRL dated on 2010-12-23: Certriad Development Discontinued - Analyst Blog

Financial news for CRL dated on 2010-12-23: Certriad Development Discontinued - Analyst Blog

Financial news for CRL dated on 2010-12-23: Hapoaliom Views Arena's Lorcaserin As Unapprovable

Financial news for CRL dated on 2010-12-23: Label Expansion Sought for Byetta - Analyst Blog

Financial news for CRL dated on 2010-12-23: Label Expansion Sought for Byetta - Analyst Blog

Financial news for CRL dated on 2010-12-22: Cumberland Pharmaceuticals Falls 10.9% On FDA News (CPIX)

Financial news for CRL dated on 2010-12-22: Another Setback for AstraZeneca - Analyst Blog

Financial news for CRL dated on 2010-12-22: Another Setback for AstraZeneca - Analyst Blog

Financial news for CRL dated on 2010-12-22: Arena Pharmaceuticals Set To Reopen 8:15am After FDA End-Of-Review (ARNA)

Financial news for CRL dated on 2010-12-22: Cumberland Pharmaceuticals FDA Rejection In CRL (CPIX)

Financial news for CRL dated on 2010-12-21: King Pharma Files NDA for Pain Drug - Analyst Blog

Financial news for CRL dated on 2010-12-21: King Pharma Files NDA for Pain Drug - Analyst Blog

Financial news for CRL dated on 2010-12-17: Regulatory Setback for AstraZeneca - Analyst Blog

Financial news for CRL dated on 2010-12-17: Regulatory Setback for AstraZeneca - Analyst Blog

Financial news for CRL dated on 2010-12-17: Charles River's Business Outlook - Analyst Blog

Financial news for CRL dated on 2010-12-17: Charles River's Business Outlook - Analyst Blog

Financial news for CRL dated on 2010-12-14: J.P. Morgan Reports Disappointing Guidance for Charles River Laboratories

Financial news for CRL dated on 2010-12-14: Charles River Discusses Business Outlook (CRL)

Financial news for CRL dated on 2010-12-14: VIVUS Submits Briefing Document to FDA, Announces Follow-up Meeting (VVUS)

Financial news for CRL dated on 2010-12-10: Neutral on MannKind - Analyst Blog

Financial news for CRL dated on 2010-12-10: Neutral on MannKind - Analyst Blog

Financial news for CRL dated on 2010-12-10: Charles River Laboratories to Report Guidance

Financial news for CRL dated on 2010-12-09: Cramer's 'Mad Money' Recap: Santa Bull's 12 Gifts (Update 1)

Financial news for CRL dated on 2010-12-09: Goldman Sachs Maintains CRL Rating And PT Ahead Of Guidance Call

Financial news for CRL dated on 2010-12-03: Setback for Valeant Epilepsy Drug - Analyst Blog

Financial news for CRL dated on 2010-12-03: Setback for Valeant Epilepsy Drug - Analyst Blog

Financial news for CRL dated on 2010-12-03: Setback for Valeant Epilepsy Drug - Analyst Blog

Financial news for CRL dated on 2010-12-03: Setback for Valeant Epilepsy Drug - Analyst Blog

Financial news for CRL dated on 2010-12-03: An Update on Alexza Pharma (ALXA) - Analyst Blog

Financial news for CRL dated on 2010-12-03: An Update on Alexza Pharma (ALXA) - Analyst Blog

Financial news for CRL dated on 2010-11-30: Good News for Spectrum Pharma - Analyst Blog

Financial news for CRL dated on 2010-11-30: Good News for Spectrum Pharma - Analyst Blog

Financial news for CRL dated on 2010-11-24: Amylin Stays Neutral - Analyst Blog

Financial news for CRL dated on 2010-11-24: Amylin Stays Neutral - Analyst Blog

Financial news for CRL dated on 2010-11-12: Charles River Misses, Trims Outlook - Analyst Blog

Financial news for CRL dated on 2010-11-12: Zacks Analyst Blog Highlights: Lions Gate Entertainment, Amylin Pharmaceuticals, Amylin Pharmaceuticals, Eli Lilly, Alkermes and Novo Nordisk - Press Releases

Financial news for CRL dated on 2010-11-11: Wider Loss at Amylin - Analyst Blog



Financial news for CRL dated on 2010-11-09: Pharma & Biotech Industry Outlook - Nov. 2010 - Zacks Analyst Interviews

Financial news for CRL dated on 2010-11-09: Pharma & Biotech Industry Outlook - Nov. 2010 - Industry Outlook

Financial news for CRL dated on 2010-11-09: Pharma and Biotech Industry Outlook - Nov. 2010 - Industry Outlook

Financial news for CRL dated on 2010-11-05: Narrower Q3 Loss at CTIC - Analyst Blog

Financial news for CRL dated on 2010-11-04: J.P. Morgan Has A Note On Charles River Laboratories After Earnings (CRL)

Financial news for CRL dated on 2010-11-02: Loss at MNKD Wider than Expected - Analyst Blog

Financial news for CRL dated on 2010-11-01: Jefferies Remains Cautious On Vivus Pending Qnexa Approval

Financial news for CRL dated on 2010-10-29: J.P. Morgan Upgrades Vivus (VVUS)

Financial news for CRL dated on 2010-10-25: Rude Shock for Arena Pharma - Analyst Blog

Financial news for CRL dated on 2010-10-25: FDA Issues Complete Response For Arena's Lorcaserin

Financial news for CRL dated on 2010-10-20: Rude Shock for Amylin - Analyst Blog

Financial news for CRL dated on 2010-10-20: Collins Stewart Lowers Amylin Price Target

Financial news for CRL dated on 2010-10-13: Charles River Announces Exclusive License with Transposagen Biopharmaceuticals, Inc.

Financial news for CRL dated on 2010-10-07: Cell Therapeutics Cut to Underperform - Analyst Blog

Financial news for CRL dated on 2010-09-20: CTIC Stays Neutral - Analyst Blog

Financial news for CRL dated on 2010-09-14: Forest Labs Responds to CRL - Analyst Blog

Financial news for CRL dated on 2010-09-14: CTIC to Challenge FDA Decision - Analyst Blog

Financial news for CRL dated on 2010-09-10: MannKind Evenly Poised - Analyst Blog

Financial news for CRL dated on 2010-09-07: Red Signal for AstraZeneca Drug - Analyst Blog

Financial news for CRL dated on 2010-08-30: Jefferies Sees Limited Upside In Charles River Laboratories (CRL)

Financial news for CRL dated on 2010-08-05: CRL Misses, Curbs Expectations - Analyst Blog

Financial news for CRL dated on 2010-08-03: MannKind Q2 Loss Shrinks - Analyst Blog

Financial news for CRL dated on 2010-08-03: Price Target For Charles River Laboratories Revised Downwards (CRL)

Financial news for CRL dated on 2010-08-02: Charles River Falls 4% After Missing Estimates (CRL)

Financial news for CRL dated on 2010-08-02: Charles River Misses Estimates (CRL)

Financial news for CRL dated on 2010-07-30: Piper Jaffray report on WuXi Pharma Tech, Inc

Financial news for CRL dated on 2010-07-30: Charles River Scraps WuXi Takeover Bid

Financial news for CRL dated on 2010-07-29: JANA Partners Urges All Charles River Shareholders to Vote Against Proposed WuXi Acquisition

Financial news for CRL dated on 2010-07-23: Good News for MannKind - Analyst Blog

Financial news for CRL dated on 2010-07-21: Good News for MannKind - Analyst Blog

Financial news for CRL dated on 2010-07-21: Pharma and Biotech Industry Outlook - July 2010 - Zacks Analyst Interviews

Financial news for CRL dated on 2010-07-21: Pharma and Biotech Industry Outlook - July 2010 - Industry Outlook

Financial news for CRL dated on 2010-07-20: Pharma and Biotech Industry Outlook - July 2010 - Industry Outlook

Financial news for CRL dated on 2010-07-16: JANA Partners Addresses Charles River's Latest Defense of Proposed WuXi Acquisition (CRL, WX)

Financial news for CRL dated on 2010-07-15: Charles River Schedules The Release Of Second-Quarter Results

Financial news for CRL dated on 2010-06-30: Encouraging Data on MNKD's Afrezza - Analyst Blog

Financial news for CRL dated on 2010-06-11: MannKind Presents Positive Data - Analyst Blog

Financial news for CRL dated on 2010-06-02: Jefferies Reiterates Hold Rating on Charles River (CRL)

Financial news for CRL dated on 2010-05-27: Update on Xenoport's Horizant - Analyst Blog

Financial news for CRL dated on 2010-05-18: Target Date for Cadence Drug - Analyst Blog

Financial news for CRL dated on 2010-05-05: Bullish Bet on Charles River Labs

Financial news for CRL dated on 2010-05-03: MannKind Loss Shrinks - Analyst Blog

Financial news for CRL dated on 2010-04-26: Afternoon Market Update Charles River Laboratories (NYSE: CRL), WuXi PharmaTech (WX), Duke Energy (NYSE: DUK), PPL (NYSE: PPL), CKE Restaurants (NYSE: CKR)

Financial news for CRL dated on 2010-04-26: Charles River (CRL) To Enter China With An Acquisition

Financial news for CRL dated on 2010-04-26: Company News for April 26, 2010 - Corporate Summary

Financial news for CRL dated on 2010-04-26: Charles River To Buy WuXi For \$1.6 Billion

Financial news for CRL dated on 2010-04-22: Theravance's Loss Widens - Analyst Blog

Financial news for CRL dated on 2010-04-16: Cell Therapeutics Cuts Jobs - Analyst Blog

Financial news for CRL dated on 2010-04-09: Cell's Pixantrone Denied Approval - Analyst Blog

Financial news for CRL dated on 2010-04-01: 21 Long Trade Setups with Stop-Losses

Financial news for CRL dated on 2010-03-31: FDA Accepts Savient Drug BLA - Analyst Blog

Financial news for CRL dated on 2010-03-16: Setback for MannKind - Analyst Blog

Financial news for CRL dated on 2010-03-15: Bayer Downgraded to Underperform - Analyst Blog

Financial news for CRL dated on 2010-02-22: J&J Returns Drug Rights - Analyst Blog

Financial news for CRL dated on 2010-02-19: Pipeline Setback for Glaxo - Analyst Blog

Financial news for CRL dated on 2010-02-12: Theravance Misses Estimates - Analyst Blog

Financial news for CRL dated on 2010-02-11: Charles River Laboratories' (CRL) Estimates Lowered

Financial news for CRL dated on 2010-02-09: Trade Ideas for February 9, 2010

Financial news for CRL dated on 2010-01-14: Wednesday's Hot Stocks: Finding A Rose Among Many Thorns

Financial news for CRL dated on 2010-01-13: Tuesday's Breakout Stocks: Pumping up Your Portfolio with NBTY

Financial news for CRL dated on 2010-01-12: Charles River Laboratories (CRL) To Suspend Operations Of Preclinical Services

Financial news for CRL dated on 2010-01-04: Zacks Analyst Blog Highlights: Johnson & Johnson, ViroPharma, Theravance, Cubist Pharmaceutical and Pfizer - Press Releases

Financial news for CRL dated on 2009-12-31: Pipeline Setback for JNJ - Analyst Blog

Financial news for CRL dated on 2009-12-11: Setback for Endo Pharma - Analyst Blog

Financial news for CRL dated on 2009-12-07: AstraZeneca: More Good News - Analyst Blog

Financial news for CRL dated on 2009-11-30: Setback for Theravance - Analyst Blog

Financial news for CRL dated on 2009-11-20: Biogen's Rituxan Label Expansion Delayed - Analyst Blog

Financial news for CRL dated on 2009-11-17: GENZ's Lumizyme Approval Delayed - Analyst Blog

Financial news for CRL dated on 2009-08-07: TheFortuneFinancial.com Free Market Research on BSX, ARW, CVG, WY, TS and CRL